Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD HOC Trial: AI-Based Drug Dosing in Hepatocellular Carcinoma
NCT05669339Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Dec 2024
- Primary completion
- Apr 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib, sonidegib, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in hepatocellular carcinoma (HCC), sponsored by University of Florida. Started Dec 2024; status: recruiting.
02
Drugs
sorafenibsonidegibirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05669339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669339.